Zur Kurzanzeige

2018-06-05Zeitschriftenartikel DOI: 10.25646/5684
Carbapenem non-susceptibility of Klebsiella pneumoniae isolates in hospitals from 2011 to 2016, data from the German Antimicrobial Resistance Surveillance (ARS)
dc.contributor.authorKoppe, Uwe
dc.contributor.authorvon Laer, Anja
dc.contributor.authorKroll, Lars E.
dc.contributor.authorNoll, Ines
dc.contributor.authorFeig, Marcel
dc.contributor.authorSchneider, Marc
dc.contributor.authorClaus, Hermann
dc.contributor.authorEckmanns, Tim
dc.contributor.authorAbu Sin, Muna
dc.date.accessioned2018-09-12T14:55:00Z
dc.date.available2018-09-12T14:55:00Z
dc.date.issued2018-06-05none
dc.identifier.other10.1186/s13756-018-0362-9
dc.identifier.urihttp://edoc.rki.de/176904/5749
dc.description.abstractBackground: Carbapenem resistance in Klebsiella pneumoniae is of significant public health concern and recently spread across several countries. We investigated the extent of carbapenem non-susceptibility in K. pneumoniae isolates in Germany. Methods: We analysed 2011–2016 data from the German Antimicrobial Resistance Surveillance (ARS) System, which contains routine data of antimicrobial susceptibility testing from voluntarily participating German laboratories. Klebsiella pneumoniae isolates tested resistant or intermediate against an antibiotic were classified as non-susceptible. Results: We included 154,734 isolates from 655 hospitals in the analysis. Carbapenem non-susceptibility in K. pneumoniae isolates was low in Germany 0.63% (95% CI 0.51–0.76%). However, in continuously participating hospitals the number of K. pneumoniae isolates almost doubled and we found evidence for a slowly increasing trend for non-susceptibility (OR = 1.20 per year, 95% CI 1.09–1.33, p < 0.001). Carbapenem non-susceptibility was highest among isolates from patients aged 20–39 in men but not in women. Moreover, carbapenem non-susceptibility was more frequently reported for isolates from tertiary care, specialist care, and prevention and rehabilitation care hospitals as well as from intensive care units. Co-resistance of carbapenem non-susceptible isolates against antibiotics such as tigecycline, gentamicin, and co-trimoxazole was common. Co-resistance against colistin was 13.3% (95% CI 9.8–17.9%) in carbapenem non-susceptible isolates. Conclusion: Carbapenem non-susceptibility in K. pneumoniae isolates in Germany is still low. However, it is slowly increasing and in the light of the strong increase of K. pneumoniae isolates over the last year this poses a significant challenge to public health. Continued surveillance to closely monitor trends as well as infection control and antibiotic stewardship activities are necessary to preserve treatment options.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjectKlebsiella pneumoniaeeng
dc.subjectCarbapenemeng
dc.subjectSurveillanceeng
dc.subjectAntimicrobialeng
dc.subjectResistanceeng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titleCarbapenem non-susceptibility of Klebsiella pneumoniae isolates in hospitals from 2011 to 2016, data from the German Antimicrobial Resistance Surveillance (ARS)none
dc.typearticle
dc.identifier.urnurn:nbn:de:kobv:0257-176904/5749-0
dc.identifier.doihttp://dx.doi.org/10.25646/5684
dc.type.versionpublishedVersionnone
local.edoc.container-titleAntimicrobial Resistance & Infection Controlnone
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://aricjournal.biomedcentral.com/articles/10.1186/s13756-018-0362-9none
local.edoc.container-publisher-nameBioMedCentralnone
local.edoc.container-volume7none
local.edoc.container-issue71none
local.edoc.container-firstpage1none
local.edoc.container-lastpage12none
local.edoc.rki-departmentInfektionsepidemiologienone
dc.description.versionPeer Reviewednone

Zur Kurzanzeige